MMV in partnership: the Eurartesim(®) experience

BACKGROUND: This case study describes how a public-private partnership between Medicines for Malaria Venture (MMV) and Sigma-Tau Industrie Farmaceutiche Riunite SpA achieved international regulatory approval for use of the fixed-dose artemisinin-based combination therapy dihydroartemisinin-piperaqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubben, David, Poll, Elizabeth M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691732/
https://www.ncbi.nlm.nih.gov/pubmed/23782869
http://dx.doi.org/10.1186/1475-2875-12-211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691732/
https://www.ncbi.nlm.nih.gov/pubmed/23782869
http://dx.doi.org/10.1186/1475-2875-12-211

Ejemplares similares